Clinical Scorecard: EVIDENT Initiative by ARPA-H: Advancing Behavioral Health Treatments

At a Glance

Key Highlights

• EVIDENT allocates $139.4 million to accelerate development of effective behavioral health therapies.
• Focus on objective measurement tools to replace subjective, trial-and-error approaches in mental health care.
• Supports research on rapid-acting treatments including psychedelics, neuromodulation, and digital interventions.

Guideline-Based Recommendations

Diagnosis

• Utilize multimodal, longitudinal data from clinical trials and real-world settings to develop objective behavioral health measures.
• Incorporate biomarkers such as cortisol, estradiol, inflammatory markers, and microbiome data to assess mental health states.

Management

• Apply validated FDA-ready clinical endpoints to personalize and optimize rapid-acting behavioral health therapies.
• Leverage neuromodulation, neuroplastogens, and psychedelic therapies with real-time biomarker monitoring to determine treatment efficacy.
• Match treatments to individuals based on predictive data to reduce failed treatment attempts.

Monitoring & Follow-up

• Use continuous wearable device data integrated with electronic health records for early prediction and prevention of behavioral health disorders.
• Implement objective, scalable measures to monitor physiological changes during treatment.
• Track treatment response through biomarkers and neurobiological mechanisms to guide ongoing care.

Risks

• Ensure safety and regulatory compliance in the use of psychedelics and neuromodulation therapies.
• Address potential variability in individual responses through personalized data-driven approaches.

Patient & Prescribing Data

Individuals with serious mental illness including anxiety, depression, PTSD, addiction, and Veterans

Data-driven matching of rapid-acting therapies to patients aims to improve efficacy and reduce trial-and-error prescribing; ongoing clinical trials include psilocybin and neuromodulation interventions.

Clinical Best Practices

• Incorporate objective biomarkers and multimodal data to guide behavioral health treatment decisions.
• Adopt rapid, data-informed endpoints to accelerate therapy validation and regulatory approval.
• Engage in multidisciplinary research collaborations to integrate clinical, biological, and digital health data.
• Prioritize personalized treatment approaches based on predictive analytics and physiological monitoring.

References

• ARPA-H EVIDENT Initiative Announcement
• Trump Administration Executive Order on Accelerating Medical Treatments for Serious Mental Illness